Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€194.35

€194.35

0.570%
1.1
0.570%
€256.90
 
02.04.26 / Tradegate WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Resmed Inc. Stock

The Resmed Inc. stock is trending slightly upwards today, with an increase of €1.10 (0.570%) compared to yesterday's price.
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Resmed Inc..
With a target price of 256 € there is a positive potential of 31.72% for Resmed Inc. compared to the current price of 194.35 €.

Pros and Cons of Resmed Inc. in the next few years

Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Resmed Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Resmed Inc. 0.570% 0.673% -11.699% -5.426% -6.787% -1.834% 17.752%
Veeva Systems A 0.600% -2.520% -2.803% -27.754% -21.227% -10.971% -33.634%
Thermo Fisher Scientific Inc. -0.550% 0.365% -2.069% -5.482% -13.820% -19.853% 9.910%
Intuitive Surgical Inc -2.190% -3.626% -7.644% -16.148% -19.851% 66.440% 85.162%

Comments

ResMed (NYSE:RMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Ratings data for RMD provided by MarketBeat
Show more

ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at KeyCorp.
Ratings data for RMD provided by MarketBeat
Show more

ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for RMD provided by MarketBeat
Show more

News

Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.